← All trials
NCT06013319
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 1, 2023
- Primary completion
- Apr 30, 2026
- Completion date
- Oct 30, 2026
- First posted
- Aug 28, 2023
- Last posted
- Sep 11, 2023
- Enrollment
- 178
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Shandong Province Qianfoshan HospitalLead sponsor
- Shandong Province Qianfoshan HospitalSponsor investigator
- Qianfo Mountain Hospital, Shandong ProvinceStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.